Market revenue in 2022 | USD 232.5 million |
Market revenue in 2030 | USD 379.5 million |
Growth rate | 6.3% (CAGR from 2022 to 2030) |
Largest segment | Estrogen and progesterone replacement therapy |
Fastest growing segment | Parathyroid Hormone replacement |
Historical data | 2018 - 2021 |
Base year | 2022 |
Forecast period | 2023 - 2030 |
Quantitative units | Revenue in USD million |
Market segmentation | Estrogen and Progesterone Replacement Therapy, HGH replacement therapy, Thryoid hormone replacement therapy, Testosterone Replacement Therapy, Parathyroid Hormone replacement |
Key market players worldwide | Eli Lilly and Co, Bayer AG, Hisamitsu Pharmaceutical Co Inc, Pfizer Inc, Merck & Co Inc, Viatris Inc, Novo Nordisk A/S ADR, AbbVie Inc, Roche Holding AG ADR, Ascend Wellness Holdings Inc |
No credit card required*
Name | Profile | # Employees | HQ | Website |
---|
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to hormone replacement therapy market will help companies and investors design strategic landscapes.
Estrogen and progesterone replacement therapy was the largest segment with a revenue share of 55.7% in 2022. Horizon Databook has segmented the Mexico hormone replacement therapy market based on estrogen and progesterone replacement therapy, hgh replacement therapy, thryoid hormone replacement therapy, testosterone replacement therapy, parathyroid hormone replacement covering the revenue growth of each sub-segment from 2018 to 2030.
Mexico is the second-largest market for hormone replacement therapy, after Brazil in this region due to the increasing prevalence o f diseases. According to National Library of Medicine (2017), the estimated prevalence of thyroid dysfunction was 23.7%. Of this, the prevalence o f subclinical hypothyroidism was 1 5.4% and overt hypothyroidism was 7.2%.
This oral tablet maintains adequate hormone levels, curing signs and symptoms o f hypothyroidism. Thus, increasing prevalence of hypothyroidism increases the demand for these products, thereby driving market growth. Moreover, the presence of a large number of healthcare service providers such as hospitals & clinics and a large buyer base is expected to fuel market growth.
For instance, Russald Clinic i n Mexico is the major provider o f hormonal replacement therapy treatments to patients at an affordable cost. Some of these therapies are testosterone replacement therapy (USD 500) and progesterone & estrogen replacement therapy (USD 350).
Horizon Databook provides a detailed overview of country-level data and insights on the Mexico hormone replacement therapy market , including forecasts for subscribers. This country databook contains high-level insights into Mexico hormone replacement therapy market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account